Yue Huang | Associate Director
Astrazeneca

Yue Huang, Associate Director, Astrazeneca

Yue Huang received her Ph.D. from University of Washington. After joining AstraZeneca in 2016, she focused on supporting various projects with LCMS-based techniques. The LCMS bioanalytical techniques have been applied to support various project from preclinical to early clinical stage, ranging from therapeutic peptides to bio-conjugates such as ADCs, as well as small molecule excipients and monoclonal antibodies. Yue have extensive experience with method development of hybrid LC-MS/MS assays for the absolute quantification and comprehensive characterization of the in vivo biotransformations of structurally complex molecules. The results from her work informed key decision-making for several drug candidates.

Appearances:



Festival of Biologics Day 3 @ 11:30

Advanced Assessments of ADC Biotransformation by Mass Spectrometry

  1. Complexity of ADC bioanalysis with consideration of ADC biotransformation
  2. LBA-LCMS approach for ADC biotransformation, with both bottom up surrogate peptide approach and intact approach
  3. Multiple case studies, highlighting the bioanalysis strategy selection when facing different stage of ADC drug development.
last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers